Repligen Corporation (NASDAQ:RGEN) has received an average recommendation of “Buy” from the six brokerages that are currently covering the firm, Marketbeat reports. Three research analysts have rated the stock with a hold rating, one has issued a buy rating and one has assigned a strong buy rating to the company. The average 12-month target price among brokers that have issued ratings on the stock in the last year is $41.00.

A number of research firms have recently commented on RGEN. BidaskClub upgraded Repligen Corporation from a “buy” rating to a “strong-buy” rating in a report on Saturday, June 24th. Janney Montgomery Scott raised their price objective on Repligen Corporation from $42.00 to $47.00 in a report on Friday, June 23rd. Jefferies Group LLC reiterated a “hold” rating and set a $40.00 target price (up from $33.00) on shares of Repligen Corporation in a report on Wednesday, June 28th. Zacks Investment Research downgraded Repligen Corporation from a “buy” rating to a “hold” rating in a report on Wednesday, July 5th. Finally, First Analysis reiterated an “equal weight” rating and set a $40.00 target price on shares of Repligen Corporation in a report on Friday, April 21st.

Large investors have recently bought and sold shares of the company. Ameritas Investment Partners Inc. acquired a new stake in Repligen Corporation during the first quarter valued at about $103,000. Victory Capital Management Inc. increased its stake in Repligen Corporation by 76.6% in the first quarter. Victory Capital Management Inc. now owns 3,400 shares of the biotechnology company’s stock valued at $120,000 after buying an additional 1,475 shares in the last quarter. State of Alaska Department of Revenue increased its stake in Repligen Corporation by 2.2% in the first quarter. State of Alaska Department of Revenue now owns 3,740 shares of the biotechnology company’s stock valued at $131,000 after buying an additional 80 shares in the last quarter. JPMorgan Chase & Co. increased its stake in Repligen Corporation by 31.9% in the first quarter. JPMorgan Chase & Co. now owns 3,755 shares of the biotechnology company’s stock valued at $133,000 after buying an additional 908 shares in the last quarter. Finally, Envestnet Asset Management Inc. increased its stake in Repligen Corporation by 3.6% in the fourth quarter. Envestnet Asset Management Inc. now owns 6,388 shares of the biotechnology company’s stock valued at $197,000 after buying an additional 223 shares in the last quarter. Institutional investors own 96.45% of the company’s stock.

Shares of Repligen Corporation (NASDAQ:RGEN) traded down 0.70% during mid-day trading on Wednesday, reaching $42.30. 273,635 shares of the company traded hands. Repligen Corporation has a 52 week low of $25.93 and a 52 week high of $46.81. The firm has a market capitalization of $1.44 billion, a price-to-earnings ratio of 111.61 and a beta of 1.32. The firm has a 50-day moving average price of $39.63 and a 200 day moving average price of $34.54.

Repligen Corporation (NASDAQ:RGEN) last released its quarterly earnings data on Thursday, May 4th. The biotechnology company reported $0.15 EPS for the quarter, topping analysts’ consensus estimates of $0.13 by $0.02. The company had revenue of $30.59 million for the quarter, compared to the consensus estimate of $29.28 million. Repligen Corporation had a return on equity of 9.57% and a net margin of 11.93%. The company’s quarterly revenue was up 21.9% compared to the same quarter last year. During the same period last year, the business posted $0.12 EPS. On average, analysts anticipate that Repligen Corporation will post $0.55 earnings per share for the current year.

COPYRIGHT VIOLATION WARNING: This article was reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this article on another domain, it was copied illegally and reposted in violation of international copyright and trademark law. The correct version of this article can be accessed at https://www.thecerbatgem.com/2017/07/16/brokerages-set-repligen-corporation-rgen-pt-at-37-25-updated-updated-updated.html.

About Repligen Corporation

Repligen Corporation is a bioprocessing company. The Company is focused on the development, manufacture and commercialization of products used to improve the interconnected phases of the biological drug manufacturing process. The Company’s portfolio includes protein products, chromatography products, and filtration products.

Receive News & Stock Ratings for Repligen Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen Corporation and related stocks with our FREE daily email newsletter.